Boehringer Ingelheim Corporation Release: Pradaxa® (Dabigatran Etexilate) 150mg Bid Continues To Be The Only Oral Anticoagulant Which Showed Superior Ischaemic Stroke Reduction Vs. Warfarin In Its Pivotal Study RE-LY®

Published: Nov 25, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Prevention of ischaemic stroke (a stroke caused by a blood clot)9 is the reason to treat patients with atrial fibrillation (AF) with an anticoagulant treatment.10 Examining all phase III trial analyses now available (RE-LY®3,4 [Pradaxa® (dabigatran etexilate)], ROCKET-AF5 [rivaroxaban], ARISTOTLE6 [apixaban]) as well as ENGAGE-AF-TIMI 481,2 [edoxaban], for which new data were presented on 19 November at the American Heart Association’s Scientific Sessions), Pradaxa® 150mg bid continues to be the only NOAC to offer a statistically significant superior reduction in the risk of ischaemic stroke versus well controlled warfarin.3,4 In all of the trials, ischaemic stroke was included as part of the composite of stroke (ischaemic and haemorrhagic or systemic embolism), the primary study outcome.1-6

Help employers find you! Check out all the jobs and post your resume.

Back to news